ERBB2 and breast cancer: This analysis revealed that young age (< 50 years) (OR 2.57, 95% CI 1.04–6.88), lymph node-positive breast cancer (OR 2.10, 95% CI 1.03–4.39), and HER2-positive subtype breast cancer (OR 5.24, 95% CI 1.40–25.90) were associated with an increased likelihood of recurrence detection outside of scheduled surveillance (Table 5).